[Stock with unusual movement] Modern Biotechnology, prostate cancer treatment clinical trial modification approved and gaining strength

Modern Biopharma is showing strength following the news of approval for the Phase 1 clinical trial plan change of its candidate substance “CP-PCA07” for the treatment of castration-resistant prostate cancer.

According to the Korea Exchange’s trading and announcement system, Modern Biopharma rose 620 won (4.49%) from the previous trading day, closing at 14,420 won.

The company announced that it has received approval from the Food and Drug Safety Ministry for the change in the Phase 1 clinical trial plan of CP-PCA07. This change was made to reflect the Ministry’s rectification measures and to further clarify the clinical trial execution procedures. The reason for the change application is a manufacturer change.

The core of this clinical trial is to evaluate the safety and tolerability of combining the existing drug enzalutamide with CP-PCA07 in patients with castration-resistant prostate cancer. The primary goal is to assess the maximum tolerated dose and dose-limiting toxicity at 12 weeks of treatment to determine the recommended dose for subsequent Phase 2 clinical trials.

The clinical trial will be conducted at multiple centers, including Samsung Medical Center in Seoul, Hanlim University Sungshim Hospital, and Seoul National University Hospital, with a minimum of 3 and a maximum of 18 subjects. The company has set the trial duration to approximately 24 months from the date of approval.

Market attention is focused on this approval enabling Modern Biopharma to continue advancing its clinical trial process without interruption. Previously, after applying for the change approval, the company adjusted its clinical trial design according to the requirements of the Food and Drug Safety Ministry.

The technical basis is held by the partner company C&Pharm. C&Pharm owns patents related to formulation manufacturing and other intellectual property rights, while Modern Biopharma exercises development and commercialization rights based on its exclusive implementation rights.

However, the company stated in its announcement that the probability of final drug approval for the clinical trial drug is statistically about 10%. Investment decisions should remain cautious.